1068 completed, 222 terminated, 100 recruiting, 99 active not recruiting. 847 Phase 2, 513 Phase 1, 148 Phase 3, 81 Phase 4, 47 Not applicable.
Follow Genentech, Inc.: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Evaluate the Effects of GDC-4198 in Combination With Letrozole, Fulvestrant, or Giredestrant in Participants With Locally Advanced or Metastatic Hormone Receptor-Positive, HER2-Negatve Breast Cancer GDC-4198, Fulvestrant, Letrozole - Advanced or Metastatic Breast Cancer | Phase 1 | Not yet recruiting | Genentech, Inc. | 165 | 2026-12-15 | 2026-10-09 |
| Prospective Multiomic Analysis in Small-Cell Lung Cancer Biospecimen collection - Small Cell Cancer Of The Lung, Small Cell Lung Cancer ( SCLC ) | Recruiting | Ohio State University Comprehensive Cancer Center | 30 | 2026-11-25 | 2026-10-02 | |
| TPG: Tafasitamab, Polatuzumab Vedotin, and Glofitamab as First-line Therapy for Diffuse Large B-cell Lymphoma and High-grade B-cell Lymphoma Tafasitamab, Polatuzumab vedotin, Glofitamab - Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma | Phase 2 | Not yet recruiting | Brown University | 30 | 2026-11-01 | 2026-09-01 |
| Mosunetuzumab in Combination With Pirtobrutinib in Patients With Relapsed or Refractory Waldenstrom Macroglobulinemia (MPOWER) Pirtobrutinib, Mosunetuzumab - Waldenstrom Macroglobulinemia | Phase 2 | Not yet recruiting | University of Utah | 25 | 2026-11-01 | 2026-09-24 |
| A Study to Evaluate the Safety and Activity of GDC-7035 With Anti-Cancer Therapies in Participants With KRAS G12D-Mutated Unresectable Advanced or Metastatic Colorectal Cancer or Pancreatic Ductal Adenocarcinoma GDC-7035, Panitumumab, mFOLFOX6 - Colorectal Neoplasms, Pancreatic Ductal Adenocarcinoma | Phase 1 | Not yet recruiting | Genentech, Inc. | 388 | 2026-10-31 | 2026-10-13 |
| To Evaluate the Effects of Cevostamab in Participants With Systemic Lupus Erythematosus With or Without Active Lupus Nephritis Cevostamab, Tocilizumab - Lupus Erythematosus, Systemic | Phase 1 | Recruiting | Genentech, Inc. | 46 | 2026-10-31 | 2026-10-06 |
| SX-682 and Atezolizumab for the Treatment of Advanced or Metastatic, Recurrent Non-small Cell Lung Cancer Atezolizumab, CXCR1/2 Inhibitor SX-682, Biospecimen Collection - Advanced Lung Non-Small Cell Carcinoma, Metastatic Lung Non-Small Cell Carcinoma | Phase 2 | Recruiting | University of Washington | 32 | 2026-10-06 | 2026-10-13 |
| Atezolizumab in Combination With Stereotactic Body Radiation Therapy (SBRT) and Surgery for Relapsed Osteosarcoma Surgical Resection, Stereotactic Body Radiation Therapy (SBRT), Atezolizumab - Osteosarcoma, Pulmonary Recurrence of Osteosarcoma | Phase 1 | Recruiting | Emory University | 12 | 2026-10-01 | 2026-09-30 |
| Cognitive Musical Screening and Therapeutic Innovation in Multiple Sclerosis Musical tool (Ipsilon) - Multiple Sclerosis | Not yet recruiting | Hunter College of City University of New York | 32 | 2026-10-01 | 2026-04-27 | |
| A Study to Assess the Efficacy and Safety of RO7965032 in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration RO7965032, Placebo - Geographic Atrophy Secondary to Age-Related Macular Degeneration | Phase 2 | Not yet recruiting | Genentech, Inc. | 321 | 2026-09-30 | 2026-10-01 |
| Tenecteplase (TNK) in the Treatment of Intracerebral Hemorrhage (ICH) TNK - Intracerebral Hemorrhage, Intracranial Hemorrhages | Phase 1 | Not yet recruiting | Gaurav Gupta, MD | 5 | 2026-09-15 | 2026-04-30 |
| A Study of Ocrelizumab Administered Subcutaneously in Participants With Multiple Sclerosis Who Switch From an Approved Anti-CD20 Therapy OCR SC - Multiple Sclerosis | Phase 4 | Recruiting | Genentech, Inc. | 100 | 2026-09-02 | 2026-09-30 |
| Continuous Delivery of Ranibizumab Via the Port Delivery System for Proliferative Diabetic Retinopathy-related Vitreous Hemorrhage With Pars Plana Vitrectomy and Limited PRP. PDS Implant filled with 100 mg/mL Ranibizumab, Ranibizumab - Proliferative Diabetic Retinopathy, Diabetic Retinopathy | Phase 4 | Not yet recruiting | Southeast Retina Center, Georgia | 20 | 2026-09-01 | 2026-10-13 |
| A Study of Zanubrutinib, Obinutuzumab, and Sonrotoclax in People With Mantle Cell Lymphoma Zanubrutinib, Obinutuzumab, Sonrotoclax - Mantle Cell Lymphoma | Phase 2 | Not yet recruiting | Memorial Sloan Kettering Cancer Center | 45 | 2026-09-01 | 2026-09-10 |
| Glofitamab in B-NHL Using Mid-Therapy Intratumoral Transcriptomics Glofitamab - Relapsed/Refractory Diffuse Large B-cell Lymphoma, Relapsed/Refractory Mantle Cell Lymphoma | Phase 2 | Not yet recruiting | Joshua Brody | 16 | 2026-09-01 | 2026-08-05 |
| A Study of RO7890597 in Healthy Adult Volunteers RO7890597, Placebo, Rabeprazole - Healthy Volunteers | Phase 1 | Recruiting | Genentech, Inc. | 139 | 2026-08-28 | 2026-10-16 |
| A Study Evaluating Adherence, Tolerability, and Patient Reported Outcomes of Giredestrant in Participants With ER+/HER2- Early Breast Cancer Who Are Intolerant to Adjuvant Aromatase Inhibitor Therapy (novERA Breast Cancer) Giredestrant - Early Breast Cancer | Phase 3 | Recruiting | Genentech, Inc. | 300 | 2026-08-25 | 2026-10-20 |
| A Study of Azacitidine and Venetoclax Versus a Stem Cell Transplant in People 65 Years and Older With Acute Myeloid Leukemia Azacitidine (AZA), Venetoclax, Allogeneic hematopoietic stem cell transplantation - Acute Myeloid Leukemia | Phase 2 | Withdrawn | Memorial Sloan Kettering Cancer Center | 2026-08-04 | 2026-08-05 | |
| Phase 2 Study Of Mosunetuzumab In Patients With Chronic Lymphocytic Leukemia With Positive MRD Mosunetuzumab - Lymphocytic Leukemia | Phase 2 | Recruiting | M.D. Anderson Cancer Center | 30 | 2026-07-09 | 2026-08-12 |
| A Prospective Longitudinal Analysis of Faricimab (Vabysmo 6mg) For Choroidal Neovascularization in Presumed Ocular Histoplasmosis Syndrome Faricimab Injection [Vabysmo] - Presumed Ocular Histoplasmosis | Phase 4 | Recruiting | Cincinnati Eye Institute, Southwest Ohio | 25 | 2026-07-01 | 2026-07-10 |
Showing 20 of 1633. Sign in to see all of them.
Breast Neoplasms (144) · Carcinoma, Non-Small-Cell Lung (106) · Neoplasms (67) · Lymphoma, Non-Hodgkin (52) · Lung Neoplasms (51) · Leukemia, Lymphocytic, Chronic, B-Cell (48) · Asthma (43) · Colorectal Neoplasms (42) · Glioblastoma (41) · Macular Degeneration (41) · Neoplasm Metastasis (41) · Ovarian Neoplasms (41) · Brain Neoplasms (36) · Lymphoma (33) · Arthritis, Rheumatoid (30)
Bevacizumab (328) · Rituximab (139) · atezolizumab (131) · Ranibizumab (113) · Erlotinib Hydrochloride (112) · Carboplatin (85) · Paclitaxel (81) · Trastuzumab (70) · Cyclophosphamide (57) · venetoclax (51) · Gemcitabine (49) · Omalizumab (47) · Docetaxel (45) · obinutuzumab (45) · Radiotherapy (42)
United States (1389) · Spain (122) · Canada (119) · United Kingdom (115) · Australia (98) · France (96) · Germany (95) · Italy (66) · Belgium (61) · South Korea (61) · Poland (53) · Brazil (43) · Czechia (41) · Netherlands (39) · Mexico (37)
Scott Holden, M.D. (8) · Ivor Caro, M.D. (7) · John D. Hainsworth, MD (7) · Norman Wolmark, MD (7) · Annick Desjardins, MD, FRCPC (6) · Barbara Lippe, M.D. (5) · Wolfgang Dummer, M.D. (5) · Dennis Wong, M.D. (4) · Mack Mabry, MD (4) · Michelle Freemer, M.D. (4)
PMID 36774994, PMID 24498318, PMID 26835133, PMID 35829925, PMID 37391667, PMID 17686822, PMID 26054553, PMID 26968970, PMID 27424128, PMID 27540466, PMID 27708114, PMID 27939380, PMID 28388260, PMID 28390587, PMID 29655772, PMID 30072107, PMID 30116539, PMID 30472023, PMID 31023700, PMID 31047956, PMID 31050355, PMID 31153107, PMID 31401786, PMID 31969177, PMID 32770353, PMID 33217063, PMID 33434107, PMID 35688625, PMID 39350369, PMID 39513754, PMID 18776057, PMID 19064978, PMID 19255158, PMID 19901100, PMID 20008710, PMID 20189654, PMID 20378094, PMID 20427088, PMID 20683380, PMID 20920825, PMID 21571362, PMID 21571677, PMID 21794843, PMID 22965590, PMID 22999634, PMID 23009891, PMID 23361508, PMID 23415775, PMID 23453513, PMID 23699977
2023 (19), 2016 (13), 2015 (12), 2017 (11), 2014 (9), 2009 (8), 2018 (8), P30CA093373 (7), 2025 (3), UL1RR024150 (3), 2019 (2), P30CA006516 (2), P30CA016672 (2), P30CA138292 (2), U01HL072268 (2)